491 related articles for article (PubMed ID: 15216914)
1. Development of new drugs in angiogenesis.
Ziche M; Donnini S; Morbidelli L
Curr Drug Targets; 2004 Jul; 5(5):485-93. PubMed ID: 15216914
[TBL] [Abstract][Full Text] [Related]
2. Target molecules for anti-angiogenic therapy: from basic research to clinical trials.
Hagedorn M; Bikfalvi A
Crit Rev Oncol Hematol; 2000 May; 34(2):89-110. PubMed ID: 10799835
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
4. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
5. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
6. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
Chuang CH; Liu CH; Lu TJ; Hu ML
Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
8. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
Bikfalvi A; Bicknell R
Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
[TBL] [Abstract][Full Text] [Related]
10. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
Nisato RE; Tille JC; Jonczyk A; Goodman SL; Pepper MS
Angiogenesis; 2003; 6(2):105-19. PubMed ID: 14739617
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
12. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.
Pratheeshkumar P; Kuttan G
Eur J Pharmacol; 2011 Apr; 656(1-3):10-8. PubMed ID: 21256125
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells.
Larsson H; Sjöblom T; Dixelius J; Ostman A; Ylinenjärvi K; Björk I; Claesson-Welsh L
Cancer Res; 2000 Dec; 60(23):6723-9. PubMed ID: 11118058
[TBL] [Abstract][Full Text] [Related]
14. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
15. Current protein-based anti-angiogenic therapeutics.
Chakrabarti S; Barrow CJ; Kanwar RK; Ramana V; Kanwar JR
Mini Rev Med Chem; 2014; 14(3):291-312. PubMed ID: 24552262
[TBL] [Abstract][Full Text] [Related]
16. New insights in synovial angiogenesis.
Szekanecz Z; Besenyei T; Paragh G; Koch AE
Joint Bone Spine; 2010 Jan; 77(1):13-9. PubMed ID: 20022538
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
19. The rationale and future potential of angiogenesis inhibitors in neoplasia.
Gasparini G
Drugs; 1999 Jul; 58(1):17-38. PubMed ID: 10439927
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
